Coronary artery disease is the leading cause of death in Australia. It is caused by atherosclerosis, in which plaque builds up within arteries and its rupture leads to heart attacks and strokes. Current treatments of atherosclerosis are not always effective, can have significant side effects and can adversely affect patient quality of life. Recent research suggests that plaque rupture is determined by plaque inflammation levels. We have identified a novel molecular regulator of plaque inflammation (TGFβ). Our first aim is to measure TGFβ levels in coronary blood samples and associate this with local atherosclerotic disease, with potential to develop serum TGFβ as a blood biomarker of plaque vulnerability. Our second aim is to provide proof-of-concept that nanotechnology can target TGFβ in unstable plaque cells to promote plaque stability and hence provide a potential therapy for atherosclerosis. Our research explores innovative concepts and stretches the field of atherosclerosis research to ultimately improve clinical care.
Last updated17 January 2023